GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GW642444 (25, 100 & 400 mcg/day)Drug: Salmeterol 50mcg
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT00347139
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1468
- Registration Number
- NCT00348140
- Locations
- 🇬🇧
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00348361
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)
- Conditions
- Rhinitis, Allergic, Perennial
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT00346775
- Locations
- 🇺🇸
GSK Investigational Site, Walnut Creek, California, United States
ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 180
- Registration Number
- NCT00346749
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV
- Conditions
- Rotavirus Infections
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT00346892
To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 375
- Registration Number
- NCT00345956
- Locations
- 🇻🇳
GSK Investigational Site, Nhatrang, Vietnam
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: PlaceboBiological: HPV-16/18 L1 VLP AS04 (Cervarix TM)
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 271
- Registration Number
- NCT00345878
- Locations
- 🇲🇾
GSK Investigational Site, Kuala Lumpur, Malaysia
Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above
- Conditions
- Influenza
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT00345904
- Locations
- 🇩🇪
GSK Investigational Site, Freital, Sachsen, Germany
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
- Conditions
- TetanusAcellular PertussisDiphtheria
- Interventions
- Biological: Boostrix™Biological: ADACEL®
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2337
- Registration Number
- NCT00346073
- Locations
- 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States